Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Top 4 Large-Cap Stocks With Major Short Interest: https://www.marketbeat.com/logos/articles/med_20240612135212_top-4-large-cap-stocks-with-major-short-interest.jpg
Top 4 Large-Cap Stocks With Major Short Interest

With the ongoing GameStop saga reigniting interest in meme stocks, investors, or more likely traders and speculators, are once again seeking out stocks with high short interest. As the overall

Can Viking Holdings Extend Gains from Affluent Cruisers?: https://www.marketbeat.com/logos/articles/med_20240610131935_can-viking-holdings-extend-its-gains-from-affluent.jpg
Can Viking Holdings Extend Gains from Affluent Cruisers?

Destination-focused luxury cruise operator Viking Holdings Ltd. (NYSE: VIK) went public through a $1.8 billion initial public offering (IPO) on May 1, 2024. It was priced at $24 and hasn’t

HealthEquity Stock: Leading Health Savings Account Investment: https://www.marketbeat.com/logos/articles/med_20240609114559_chart-hqy.jpg
HealthEquity Stock: Leading Health Savings Account Investment

HealthEquity Inc (NASDAQ: HQY) is one of the nation’s largest providers of health savings accounts (HSA) and consumer-directed benefits (CDB) services. Its platform enables individuals to open

Geron Corporation: FDA Approval Fuels Stock Price Surge: https://www.marketbeat.com/logos/articles/med_20240607114957_geron-corporation-fda-approval-fuels-stock-price-s.jpg
Geron Corporation: FDA Approval Fuels Stock Price Surge

The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation (NASDAQ: GERN) into the spotlight, sparking a surge in Geron’s stock price and attracting heightened attention

Novavax Stock’s Recent Surge and Future Potential: https://www.marketbeat.com/logos/articles/med_20240606112435_novavax-stocks-recent-surge-and-future-potential.jpg
Novavax Stock’s Recent Surge and Future Potential

Novavax (NASDAQ: NVAX) is a drug and vaccine manufacturer in the healthcare sector known for its efforts in the COVID-19 vaccine market. Novavax’s stock price has experienced a remarkable surge

Centene Reaffirms Guidance, But Is it Too Late?: https://www.marketbeat.com/logos/articles/med_20240602155058_chart-cnc.jpg
Centene Reaffirms Guidance, But Is it Too Late?

Managed care health insurance company Centene Inc. (NYSE: CNC) recently saw its share rebound after reaffirming its guidance. This move came just after UnitedHealth Group Inc. (NYSE: UNH) made

Hims & Hers Health Soars on Generic GLP-1 Rollout Plans: https://www.marketbeat.com/logos/articles/med_20240602154511_charte-hims.jpg
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans

Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through

Is Cigna Group the Nation's Best-Run Health Insurance Company?: https://www.marketbeat.com/logos/articles/med_20240525153829_chart-ci.jpg
Is Cigna Group the Nation's Best-Run Health Insurance Company?

Health insurance companies in the medical sector have not fared well in 2024. Medicare Advantage (MA) plans were a bountiful source of income until the second half of 2023. Humana Inc. (NYSE: HUM)

2 Stocks Providing Medical Insurance for Your Pets: https://www.marketbeat.com/logos/articles/med_20240519155501_chart-trup.jpg
2 Stocks Providing Medical Insurance for Your Pets

The pandemic triggered a surge in pet ownership as social distancing and lockdowns resulted in the need for companionship for many individuals and families. Anyone who owns a dog or cat can

CVS Health Stock Has a Silver Lining Called Value: https://www.marketbeat.com/logos/articles/med_20240519153028_chartzy-cvs.jpg
CVS Health Stock Has a Silver Lining Called Value

Integrated healthcare retailer and insurer CVS Health Co. (NYSE: CVS) stock presents a value not seen in years. The medical sector giant saw its shares punished on its Q1 2024 top and bottom line

Will the Biotech Sector Shift From Lagger to Leader?: https://www.marketbeat.com/logos/articles/med_20240509132613_will-the-biotech-sector-shift-from-lagger-to-leade.jpg
Will the Biotech Sector Shift From Lagger to Leader?

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the

AbbVie Tracking for New Highs in 2024: https://www.marketbeat.com/logos/articles/med_20240507101742_chart-abbv-572024.png
AbbVie Tracking for New Highs in 2024

Shares of AbbVie (NYSE: ABBV) fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira

Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report: https://www.marketbeat.com/logos/articles/med_20240505135039_chartszy-pfe.jpg
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report

Biopharma giant Pfizer Inc. (NYSE: PFE) has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to

Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher: https://www.marketbeat.com/logos/articles/med_20240430080639_analyst-sentiment-revenue-growth-will-lead-abbvie.jpg
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher

AbbVie Inc. (NYSE: ABBV) stock is recovering after falling over 4% in the week preceding its earnings report on April 26, 2024. As the market closed on Monday, April 29, ABBV stock posted a gain

Solarzellen von CESI liefern Strom für die Satelliten des globalen Internets: https://www.irw-press.at/prcom/images/messages/2024/74339/CESI_240424_DEPRconm.001.jpeg
Solarzellen von CESI liefern Strom für die Satelliten des globalen Internets

MAILAND, ITALIEN / ACCESSWIRE / 24. April 2024 / Die italienische Gruppe CESI hat mit einem der weltweit führenden Herstellern von Raumfahrtsystemen einen Vertrag abgeschlossen, der Optionen

CESI Solar Cells Fuels the Satellites of the Global Internet: https://www.irw-press.at/prcom/images/messages/2024/74339/CESI_240424_ENPRcom.001.jpeg
CESI Solar Cells Fuels the Satellites of the Global Internet

MILAN, ITALY / ACCESSWIRE / April 24, 2024 / The Italian group CESI has secured a contract, with options valued at over one hundred million euros over five years, with one of the world's

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?: https://www.marketbeat.com/logos/articles/med_20240421181833_charts-lly.jpg
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V (NYSE: NVO) with its Semaglutide medications

Abbott Laboratories Outlook is Healthy: Buy the Dip: https://www.marketbeat.com/logos/articles/med_20240417090953_chart-abt-4172024ver001.png
Abbott Laboratories Outlook is Healthy: Buy the Dip

Abbott Laboratories' (NYSE: ABT) share price was corrected at the end of CQ1 2024 on growth, profitability and capital returns concerns. The FQ1 results, however, belie the fear and have the market

Undervalued UnitedHealth Group Won’t Be For Long: https://www.marketbeat.com/logos/articles/med_20240416091545_chart-unh-4162024ver001.png
Undervalued UnitedHealth Group Won’t Be For Long

UnitedHealth Group's (NYSE: UNH) Q1 results were better than expected for two reasons: First, the stock price is now rebounding from long-term lows and deep value territory with ample upside

Johnson & Johnson is as Cheap as it’s Going to Get: https://www.marketbeat.com/logos/articles/med_20240416075018_chart-jnj-4162024ver001.png
Johnson & Johnson is as Cheap as it’s Going to Get

Shares of Johnson & Johnson (NYSE: JNJ) are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading

Novo Nordisk Arms Wegovy to Be a Triple Threat: https://www.marketbeat.com/logos/articles/med_20240414165029_charts-nvo.jpg
Novo Nordisk Arms Wegovy to Be a Triple Threat

Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S (NYSE: NVO). Originally purposed for Type 2 diabetes, the skyrocketing off-label

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment: https://www.marketbeat.com/logos/articles/med_20240331142316_untitledchart-akd.jpg
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment

Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The

Biotech Sector Nears Breakout: Will it Outperform in Q2?: https://www.marketbeat.com/logos/articles/med_20240401185946_biotech-sector-nears-breakout-will-it-outperform-i.jpg
Biotech Sector Nears Breakout: Will it Outperform in Q2?

The popular iShares Biotechnology ETF (NASDAQ: IBB) has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout. 

The bullish

DexCom Stock Gains from GLP-1 Diabetic Users: https://www.marketbeat.com/logos/articles/med_20240331131923_chart-dxcm.jpg
DexCom Stock Gains from GLP-1 Diabetic Users

DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to

7 Stocks That Will Drive the Weight Loss Drugs Market: https://www.marketbeat.com/logos/articles/med_20240327132929_7-stocks-that-will-drive-the-weight-loss-drugs-mar.jpg
7 Stocks That Will Drive the Weight Loss Drugs Market

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are